Source link : https://www.newshealth.biz/health-news/twice-yearly-injection-yields-zero-hiv-infections-for-high-risk-women-in-trial/
The long-acting injectable antiretroviral drug lenacapavir (Sunlenca) was highly effective in preventing HIV infection in cisgender women in high-risk countries, according to an interim analysis of the phase III PURPOSE 1 trial. Among adolescent girls and young women in South Africa and Uganda, preexposure prophylaxis (PrEP) with lenacapavir every 26 weeks reduced HIV incidence by […]
Author : News Health
Publish date : 2024-07-24 20:30:00
Copyright for syndicated content belongs to the linked Source.
Categories